Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma

被引：5
|
作者：
Vinti, Luciana [1 ]
Pagliara, Daria [1 ]
Buffardi, Salvatore [2 ]
Di Ruscio, Valentina [1 ]
Stocchi, Francesca [1 ]
Mariggio, Elena [1 ]
Parasole, Rosanna [2 ]
Di Matteo, Antonia [2 ]
Petruzziello, Fara [2 ]
Paganelli, Valeria [1 ]
De Vito, Rita [3 ]
Del Bufalo, Francesca [1 ]
Strocchio, Luisa [1 ]
Locatelli, Franco [1 ,4 ]
机构：
[1] IRCCS, Dept Paediat Haematol Oncol Cell & Gene Therapy, Bambino Gesu Childrens Hosp, Piazza S Onofrio 4, I-00165 Rome, Italy
[2] Santobono Pausilipon Childrens Hosp, Dept Paediat Haematol Oncol, Naples, Italy
[3] IRCCS, Dept Pathol, Bambino Gesu Childrens Hosp, Rome, Italy
[4] Univ Rome, Dept Pediat, Sapienza, Rome, Italy
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷 / 04期
关键词：
brentuximab vedotin; Hodgkin lymphoma; immunotherapy; pediatric; refractory; relapse; STEM-CELL TRANSPLANTATION; PHASE-II; CHILDREN; THERAPY; MULTICENTER; GEMCITABINE; VINORELBINE; RECURRENT; EFFICACY; CANCER;
D O I：
10.1002/pbc.29557
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90-120 mg/m(2) on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3-year overall and progression-free survivals are 78.1% and 67%, respectively.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
    Forlenza, Christopher J.
    Gulati, Nitya
    Mauguen, Audrey
    Absalon, Michael J.
    Castellino, Sharon M.
    Franklin, Anna
    Keller, Frank G.
    Shukla, Neerav
    BLOOD ADVANCES, 2021, 5 (24) : 5519 - 5524
  • [2] Brentuximab Vedotin in Combination with Bendamustine in Relapsed or Refractory Hodgkin Lymphoma: A Retrospective Analysis on 23 Paediatric Patients or Young Adults
    Vinti, Luciana
    Locatelli, Franco
    Merli, Pietro
    Parasole, Rosanna
    Buffardi, Salvatore
    Pillon, Marta
    Strocchio, Luisa
    Girardi, Katia
    BLOOD, 2017, 130
  • [3] Is there a place for the combination of brentuximab vedotin and bendamustine in treatment of patients with relapsed/refractory Hodgkin lymphoma?
    Chen, Robert W.
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (11)
  • [4] Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin
    Zinzani, Pier Luigi
    Derenzini, Enrico
    Pellegrini, Cinzia
    Celli, Monica
    Broccoli, Alessandro
    Argnani, Lisa
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (05) : 681 - 683
  • [5] Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy
    LaCasce, Ann
    Bociek, R. Gregory
    Matous, Jeffrey
    Sawas, Ahmed
    Caimi, Paolo
    Ansell, Stephen M.
    Islas-Ohlmayer, Miguel
    Cheung, Eric
    Agura, Edward
    Behler, Caroline
    Crosswell, Howland
    Vose, Julie M.
    Josephson, Neil
    Advani, Ranjana
    BLOOD, 2014, 124 (21)
  • [6] Brentuximab Vedotin in Combination With Bendamustine for Patients With Hodgkin Lymphoma Who Are Relapsed or Refractory After Frontline Therapy
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (02) : 8 - 10
  • [7] Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma
    Picardi, M.
    Della Pepa, R.
    Giordano, C.
    Pugliese, N.
    Mortaruolo, C.
    Trastulli, F.
    Rascato, M. G.
    Cappuccio, I
    Raimondo, M.
    Memoli, M.
    Monteverde, M.
    Mascolo, M.
    Pane, F.
    BLOOD ADVANCES, 2019, 3 (09) : 1546 - 1552
  • [8] Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients
    Ulu, Bahar Uncu
    Dal, Mehmet Sinan
    Hindilerden, Ipek Yonal
    Akay, Olga Meltem
    Mehtap, Ozgur
    Buyukkurt, Nurhilal
    Hindilerden, Fehmi
    Gunes, Ahmet Kursad
    Yigenoglu, Tugce Nur
    Basci, Semih
    Cakar, Merih Kizil
    Acik, Didar Yanardag
    Korkmaz, Serdal
    Ulas, Turgay
    Ozet, Gulsum
    Ferhanoglu, Burhan
    Nalcaci, Meliha
    Altuntas, Fevzi
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (03) : 190 - 198
  • [9] BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS A SALVAGE TREATMENT REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
    LaCasce, A.
    Bociek, G.
    Sawas, A.
    Caimi, P.
    Agura, E.
    Matous, J.
    Ansell, S.
    Crosswell, H.
    Islas-Ohlmayer, M.
    Behler, C.
    Cheung, E.
    Forero-Torres, A.
    Vose, J.
    O'Connor, O. A.
    Josephson, N.
    Advani, R.
    HAEMATOLOGICA, 2016, 101 : 45 - 46
  • [10] Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma
    Gulati, Nitya
    Boulad, Farid
    Cancio, Maria I.
    Curran, Kevin J.
    Jackson, Carolyn
    Kernan, Nancy
    Kung, Andrew L.
    O'Reilly, Richard
    Prockop, Susan
    Ramaswamy, Kavitha
    Scaradavou, Andromachi
    Spitzer, Barbara
    Shukla, Neerav
    Steinherz, Peter G.
    Forlenza, Christopher
    BLOOD, 2017, 130
12345